|1.||Levi, Marcel: 6 articles (10/2011 - 04/2003)|
|2.||van der Poll, Tom: 6 articles (10/2011 - 01/2009)|
|3.||Wada, Hideo: 5 articles (01/2014 - 04/2003)|
|4.||Hofstra, Jorrit J: 4 articles (10/2011 - 01/2009)|
|5.||Vlaar, Alexander P: 4 articles (10/2011 - 01/2009)|
|6.||Schultz, Marcus J: 4 articles (10/2011 - 01/2009)|
|7.||Nobori, Tsutomu: 4 articles (10/2005 - 04/2003)|
|8.||Ishikura, Hiroyasu: 3 articles (03/2015 - 01/2008)|
|9.||Levi, M: 3 articles (06/2014 - 12/2010)|
|10.||Matsumoto, Takeshi: 3 articles (01/2014 - 01/2005)|
09/01/1990 - "Plasma concentrations of cross linked fibrin degradation products, a marker of intravascular thrombosis and fibrinolysis, were measured in 495 patients with suspected pulmonary embolism referred for ventilation-perfusion lung scanning to determine whether concentrations are increased in pulmonary embolism and their potential use in diagnosis. "
08/01/1988 - "Changes in plasma fibrin degradation products as a marker of thrombus evolution in patients with deep vein thrombosis."
12/01/1989 - "[Relevance of fibrinogen/fibrin degradation products in the study of thrombosis]."
10/01/2011 - "Anti-PC antibody treatment aggravated pulmonary activation of coagulation as compared with control antibody treatment, as reflected by increased lung concentrations of thrombin-antithrombin complexes and fibrin degradation products, as well as intravascular thrombus formation. "
09/01/2009 - "A coagulation panel revealed a positive D-dimer test, indicative of elevated levels of fibrin degradation products due to active thrombus breakdown. "
11/01/1976 - "Laboratory confirmation consists of the demonstration of thrombocytopenia, coagulation impairment, hypofibrinogenamia, raised levels of fibrin degradation products, and positive results of para-coagulation tests. "
11/01/1975 - "Laboratory studies showed thrombocytopenia, hypofibrinogenemia, and increased fibrin degradation products. "
09/01/2003 - "Laboratory examination demonstrated severe thrombocytopenia, increased prothrombin time and a high concentration of fibrin degradation products. "
03/31/2003 - "The laboratory manifestations included severe thrombocytopenia, fibrin degradation products but no presence of schistocytes or fragmented red blood cells. "
01/01/1983 - "Endotoxin-induced elevation in fibrin degradation products was significantly decreased (P less than 0.05) during endotoxin tolerance although there was no difference in the severity of thrombocytopenia. "
11/01/1988 - "In patients with initial high but not with initial low response in fibrin degradation products renal function improved within 24 to 48 h and continued to improve thereafter; there was an immediate but temporary increase in proteinuria. "
04/01/1977 - "[Interrelation between fibrin degradation products and urinary proteinuria in diabetics]."
01/01/1979 - "The origin and mechanism of renal clearance of urinary 'fibrin-fibrinogen degradation products' (FDP) were studied in patients with renal glomerular diseases associated with heavy, non-selective proteinuria and high levels of urinary FDP. "
09/01/1977 - "These findings include the nephrotic syndrome, great variability in proteinuria and glomerular filtration rate, pulmonary embolization, sterile pyuria, hematuria, hyperchloremic acidosis, decreased renal tubular threshold for glucose and increased fibrin degradation products. "
06/01/1979 - "Proteinuria did not recur; no significant excretion of fibrin degradation products occurred; complement, urea, creatinine, and serum albumin remained within normal limits. "
|4.||Disseminated Intravascular Coagulation
01/01/2007 - "On the basis of renal dysfunction with an increase in fibrin degradation products, disseminated intravascular coagulation was considered to be concurrent with HPS. "
11/01/1996 - "Three different parameters of intravascular coagulation (activated prothombin time, fibrin degradation products, and one-step prothombin time) remained normal until after platelet numbers had declined significantly, arguing against an important role for disseminated intravascular coagulation. "
09/01/1989 - "The values for cross-linked fibrin degradation products, however, remained within normal limits during treatment, which excluded the possibility of disseminated intravascular coagulation. "
06/01/1980 - "Although elevated levels of fibrin degradation products were found in most patients, disseminated intravascular coagulation could not be diagnosed. "
07/01/1995 - "Secondary fibrinolysis then occurs with resulting thrombocytopenia, hypofibrinogenemia, and increased fibrin degradation products that can lead to disseminated intravascular coagulation. "
|5.||Venous Thrombosis (Deep-Vein Thrombosis)
05/01/2015 - "Monitoring for TEE and assessment of risk of deep vein thrombosis (DVT) by the Wells prediction rule were performed, and levels of fibrin degradation products (plasma D-dimers) were assessed before study drug administration (baseline), 2 h, and 7 days posttreatment. "
05/01/1995 - "Cross-linked fibrin degradation products have been used to detect venous thrombosis. "
11/23/1991 - "D-dimers are specific fibrin degradation products which have been measured in plasma and used as a diagnostic test for deep vein thrombosis of the lower limbs. "
12/01/1980 - "The incidence of deep vein thrombosis following transfemoral temporary pacing was prospectively assessed in 20 consecutive patients using serial 125I-fibrinogen scanning, impedance plethysmography, and measurements of fibrin degradation products. "
01/01/1977 - "The value of thermography and the determination of fibrin-fibrinogen degradation products in the diagnosis of deep venous thrombosis."
|1.||Fibrinogen (Factor I)
|2.||fibrin fragment D (D-dimer)
|3.||formycin diphosphate (FDP)
|6.||L-Lactate Dehydrogenase (Lactate Dehydrogenase)
|7.||Acute fatty liver of pregnancy
|10.||Tissue Plasminogen Activator (Alteplase)
|2.||Drug Therapy (Chemotherapy)
|4.||Cesarean Section (Caesarean Section)